Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Frontiers in Medicine|September 26, 2019
Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin CancersTakanori Hidaka, Taku Fujimura, Setsuya AibaCase Reports in Dermatology|July 19, 2012
Dermoscopy findings of pseudolymphomatous folliculitisTaku Fujimura, Takanori Hidaka, Akira Hashimoto, et al.Expert Opinion on Investigational Drugs|December 18, 2018
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trialsTaku Fujimura, Takanori Hidaka, Yumi Kambayashi, et al.Frontiers in Oncology|December 16, 2021
Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma PatientsKentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, et al.Frontiers in Medicine|August 17, 2019
Biomarkers for Predicting Efficacies of Anti-PD1 AntibodiesYumi Kambayashi, Taku Fujimura, Takanori Hidaka, et al.Nature Immunology|October 13, 2020
Environmental pollutants and the immune responseTakafumi Suzuki, Takanori Hidaka, Yoshito Kumagai, et al.Frontiers in Oncology|February 8, 2018
Tumor-Associated Macrophages: Therapeutic Targets for Skin CancerTaku Fujimura, Yumi Kambayashi, Yasuhiro Fujisawa, et al.Journal of Dermatological Science|March 18, 2011
A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-β synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growthTaku Fujimura, Kenshi Yamasaki, Takanori Hidaka, et al.Journal of Dermatological Science|June 26, 2016
Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gammaSadanori Furudate, Taku Fujimura, Aya Kakizaki, et al.Acta Dermato-Venereologica|September 6, 2012
Comparison of Foxp3+ regulatory T cells and CD163+ macrophages in invasive and non-invasive extramammary Paget's diseaseTaku Fujimura, Yumi Kambayashi, Takanori Hidaka, et al.Pageof 3